Price Alert: Shares of Kronos Bio (KRON) Trade 6.77% Higher at Midday August 5

Equities Staff  |

Kronos Bio Inc (NASDAQ: KRON) shares moved 6.77%, or $0.35 per share, as on 12:00:04 est today. Since opening at $5.42, 102,938 shares of Kronos Bio have traded hands and the stock has moved between $5.63 and $5.29.  

So far this year the company has moved YTD 60.15%.

Kronos Bio anticipates its next earnings on 2022-08-09.

For technical charts, analysis, and more on Kronos Bio visit the company profile.

About Kronos Bio Inc

Kronos Bio is a clinical-stage biopharmaceutical company dedicated to discovering and developing therapies that seek to transform the lives of those affected by cancer. The company focuses on targeting dysregulated transcription factors and the regulatory networks within cells that drive cancerous growth. Kronos Bio’s lead investigational therapy is entospletinib, a selective inhibitor targeting spleen tyrosine kinase (SYK) in development for the frontline treatment of NPM1-mutated acute myeloid leukemia (AML). The company is also developing KB-0742, an oral inhibitor of cyclin dependent kinase 9 (CDK9), for the treatment of MYC-amplified solid tumors.

To get more information on Kronos Bio Inc and to follow the company's latest updates, you can visit the company's profile page here: Kronos Bio Inc's Profile. For more news on the financial markets be sure to visit Equities News. Also, don't forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Symbol info widget is provided by TradingView based on 15-minute-delayed prices. All other article data is provided by IEX Cloud on 15-minute delayed prices or EOD company info.

Stock price data is provided by IEX Cloud on a 15-minute delayed basis. Chart price data is provided by TradingView on a 15-minute delayed basis.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer


Trending Articles

The Strong Dollar Is a Problem for Stocks
3 Ways Finance Teams Can Navigate Inflation Through Automation



Market Movers

Sponsored Financial Content